Business Context and Reporting Period
Keros Therapeutics, Inc. (KROS) filed a Current Report on Form 8-K on September 6, 2022. The company is a biopharmaceutical firm incorporated in Delaware and listed on The Nasdaq Stock Market LLC. This filing serves as a Regulation FD disclosure regarding an upcoming investor presentation.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused on a corporate event rather than a periodic financial report.
Material Changes
No material financial changes or operational updates were reported in this filing. The sole material event is the scheduled presentation by company executives at an external conference.
Guidance, Outlook, and Management Commentary
Management announced that President and CEO Jasbir Seehra and CFO Keith Regnante will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 3:40 pm Eastern time. The filing explicitly states that the information provided is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the date and time of the Morgan Stanley 20th Annual Global Healthcare Conference presentation (September 12, 2022, 3:40 pm ET).
- Confirm the identities of the presenting executives: Jasbir Seehra (CEO) and Keith Regnante (CFO).
- Review the attached press release (Exhibit 99.1) for any additional details on the presentation agenda.
- Note that this 8-K does not provide updated financial metrics; refer to the most recent 10-Q or 10-K for financial data.